What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2022-03-21 compared with 2021-03-02 · 15 added, 39 removed, 13 unchanged (81% of the section changed)

2 unchanged sentences

Market Information

Our common stock is listed on the NASDAQ

Capital Market under the ticker symbol CLRB.

On February 25, 2021 there were 181 holders

of record of our common stock.

This number does not include stockholders for whom shares were held in a “nominee”

“street”

We have not declared or paid any cash dividends

on our common stock and do not anticipate declaring or paying any cash dividends in the foreseeable future.

We currently expect

to retain future earnings, if any, for the continued development of our business.

Our transfer agent and registrar is American

Stock Transfer and Trust Company, 6201 15 th Avenue, Brooklyn, NY 11219.

Our common stock is listed on the Nasdaq Capital Market under the ticker symbol CLRB.

On February 25, 2022 there were 245 holders of record of our common stock.

This number does not include stockholders for whom shares were held in a “nominee” or “street” name.

We have not declared or paid any cash dividends on our common stock and do not anticipate declaring or paying any cash dividends in the foreseeable future.

We currently expect to retain future earnings, if any, for the continued development of our business.

Our transfer agent and registrar is American Stock Transfer and Trust Company, 6201 15 th Avenue, Brooklyn, NY 11219.

Equity compensation plans

During 2015, we issued 3,750 options to

our Chief Executive Officer that were not issued pursuant to our 2015 Stock Incentive Plan.

These options vested annually over

four years and expire ten years after the date of grant.

During 2016, we issued 7,500 options to our Chief Business Officer that

were not issued pursuant to our 2015 Stock Incentive Plan.

These options vested annually over three years and expire ten years

after the date of grant.

During 2019, we issued 90,000 options to our Chief Financial Officer that were not issued pursuant to

our 2015 Stock Incentive Plan.

During 2020, we issued 100,000 options to our Chief Medical Officer that were not issued pursuant

to our 2015 Stock Incentive Plan.

These options vest annually over three years and expire ten years after the date of grant.

all option issuances, the option price per share is not less than the fair market value of our common stock on the date of grant.

The following table provides information

as of December 31, 2020 regarding shares authorized for issuance under our equity compensation plans, including individual compensation

arrangements.

The following table provides information as of December 31, 2021, regarding shares authorized for issuance under our equity compensation plans, including individual compensation arrangements.

Equity compensation plan information

Plan category

Number of shares to

be issued upon

exercise of outstanding

options and rights (#)

Weighted-average

exercise price of

options and rights ($)

Number of shares

Weighted-average

remaining available for

Number of shares to

exercise price of

future issuance under

be issued upon

equity compensation plans

exercise of outstanding

(excluding shares reflected

Plan category

options and rights (#)

and rights ($)

in column (a)) (#)

1 unchanged sentence

Equity compensation plans not approved by stockholders

Selected Financial Data.

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity